London’s FTSE 100 experienced an uptick on Tuesday, buoyed by the performance of pharmaceutical stocks following AstraZeneca’s decision to acquire a $2 billion stake in Summit Therapeutics, aimed at furthering cancer research. The blue-chip FTSE 100 index rose 0.34% to 10,721.48 points by 0925, while the midcap FTSE 250 climbed 0.24%. Pharma sector opens new Read More
The UK’s blue-chip index, FTSE 100, experienced a decline on Tuesday, primarily influenced by the performance of GSK. This movement followed the healthcare company’s announcement regarding its intention to acquire shares of U.S.-based drug developer Nuvalent for $10.6 billion, a strategic move aimed at enhancing its lung cancer treatment portfolio. The blue-chip FTSE 100 index Read More
The FTSE 100 index saw a downturn following its record high on Tuesday, as declines in AstraZeneca shares and energy stocks overshadowed the gains made by miners. Investors are exercising caution in anticipation of the Bank of England’s policy meeting scheduled for later this week. The blue-chip FTSE 100 index was down 0.2% at 1039 Read More
